

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

NALOX-1 PHARMACEUTICALS, LLC,  
Petitioner

v.

OPIANT PHARMACEUTICALS, INC.,  
Patent Owner

---

IPR2019-00686  
U.S. Patent No. 9,211,253

---

**DECLARATION OF MAUREEN DONOVAN, Ph.D.**

*Inter Partes Review of U.S. Patent No. 9,211,253  
Declaration of Maureen Donovan, Ph.D. (Exhibit 1002)*

**TABLE OF CONTENTS**

I.	OVERVIEW .....	1
II.	MY BACKGROUND AND QUALIFICATIONS .....	8
III.	LEGAL STANDARDS .....	10
	A. Person of ordinary skill in the art.....	10
	B. Claim construction .....	12
	C. Anticipation and obviousness.....	13
	D. Written description and priority .....	16
IV.	THE '253 PATENT AND ITS CLAIMS .....	16
	A. Background of the art pertinent to the '253 Patent .....	18
	1. Opioid overdose .....	18
	2. Prior intranasal formulations of naloxone .....	20
	3. Development of a new intranasal naloxone formulation.....	21
	(a) Physical and chemical properties of naloxone .....	22
	(b) Stability of the Formulation.....	25
	(c) Nasal physiology. ....	28
	(d) Drug exposure attributes for an improved intranasal formulation of naloxone.....	29
	(e) Choice of pharmaceutical excipients to achieve the desired exposure and stability attributes.....	31
	(f) Choice of delivery device .....	48
	(g) The properties of the nasal spray delivered by the spray device. ....	49
	B. Claim 1 of the '253 patent.....	56

*Inter Partes Review of U.S. Patent No. 9,211,253  
Declaration of Maureen Donovan, Ph.D. (Exhibit 1002)*

C.	Dependent claims 2–29 of the '253 patent.....	57
D.	The '253 patent lacks priority to U.S. Provisional Application No. 61/953,379.....	60
E.	Orange Book listing of the '253 patent.....	62
V.	CLAIM CONSTRUCTION .....	63
1.	“pre-primed” .....	64
2.	“delivery time” .....	64
3.	“90% confidence interval for dose delivered per actuation is $\pm$ about 2.0%,” and “95% confidence interval for dose delivered per actuation is $\pm$ about 2.5%” .....	64
VI.	PUBLIC ACCESSIBILITY OF THE PRIOR ART.....	65
VII.	BASIS OF MY ANALYSIS WITH RESPECT TO OBVIOUSNESS.....	65
A.	A Formulator POSA reading Wyse in view of HPE would have had ample reason and know-how to arrive at the subject matter of claims 1–3 and 16–24.....	65
1.	Claim 1 .....	66
(a)	Preamble: “A single-use, pre-primed device adapted for nasal delivery of a pharmaceutical composition to a patient by one actuation of said device into one nostril of said patient, having a single reservoir comprising” .....	67
(b)	1.1: “a pharmaceutical composition which is an aqueous solution of about 100 $\mu$ L comprising:” .....	69
(c)	1.2: “about 4 mg naloxone hydrochloride or a hydrate thereof;” .....	71
(d)	1.3: “between about 0.2 mg and about 1.2 mg of an isotonicity agent;” .....	73
(e)	1.4: “between about 0.005 mg and about 0.015 mg of a preservative;” .....	74

*Inter Partes Review of U.S. Patent No. 9,211,253  
Declaration of Maureen Donovan, Ph.D. (Exhibit 1002)*

(f)	1.5: “about 0.2 mg of a stabilizing agent;” .....	81
(g)	1.6: “an amount of an acid sufficient to achieve a pH of 3.5-5.5.” .....	83
2.	Claim 2 .....	84
(a)	“the isotonicity agent is NaCl;” .....	84
(b)	“the preservative is benzalkonium chloride;” .....	84
(c)	“the stabilizing agent is disodium edetate;” .....	88
(d)	“and the acid is hydrochloric acid.” .....	88
3.	Claim 3 .....	88
(a)	“about 4.4 mg naloxone hydrochloride dihydrate;” .....	88
(b)	“about 0.74 mg NaCl;” .....	89
(c)	“about 0.01 mg benzalkonium chloride;” .....	93
(d)	“about 0.2 mg disodium edetate;” .....	93
(e)	“and an amount of hydrochloric acid sufficient to achieve a pH of 3.5-5.5.” .....	93
4.	Claim 16 .....	94
5.	Claim 17 .....	95
6.	Claim 18 .....	97
7.	Claim 19 .....	97
8.	Claims 20–23 .....	99
9.	Claim 24 .....	103
B.	A Formulator POSA reading Wyse in view of Djupesland and HPE would have had ample reason and know-how to arrive at the subject matter of claims 4–7 and 10–14.....	105
1.	Claim 4 .....	106

*Inter Partes Review of U.S. Patent No. 9,211,253  
Declaration of Maureen Donovan, Ph.D. (Exhibit 1002)*

2.	Claim 5 .....	108
3.	Claim 6 .....	111
4.	Claim 7 .....	112
5.	Claims 10–11 .....	113
6.	Claims 12–14 .....	115
C.	A Formulator POSA reading Wyse in view of Djupesland, HPE, and the '291 patent would have had ample reason and know-how to arrive at the subject matter of claims 8–9. ....	118
D.	A Formulator POSA reading Wang in view of Djupesland, HPE, Bahal, and Kushwaha would have had ample reason and know-how to arrive at the subject matter of claims 1–7, 12–14, and 16. ...	125
1.	Claim 1 .....	125
(a)	Preamble: “A single-use, pre-primed device adapted for nasal delivery of a pharmaceutical composition to a patient by one actuation of said device into one nostril of said patient, having a single reservoir comprising” .....	126
(b)	1.1: “a pharmaceutical composition which is an aqueous solution of about 100 µL comprising:” .....	129
(c)	1.2: “about 4 mg naloxone hydrochloride or a hydrate thereof;” .....	132
(d)	1.3: “between about 0.2 mg and about 1.2 mg of an isotonicity agent;” .....	135
(e)	1.4: “between about 0.005 mg and about 0.015 mg of a preservative;” .....	137
(f)	1.5: “about 0.2 mg of a stabilizing agent;” .....	146
(g)	1.6: “an amount of an acid sufficient to achieve a pH of 3.5-5.5.” .....	154
2.	Claim 2 .....	155

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.